医学
放射性核素治疗
耐火材料(行星科学)
放射性碘疗法
甲状腺癌
核医学
甲状腺
放射性核素
癌症研究
内科学
量子力学
天体生物学
物理
作者
Hao Fu,Jingxiong Huang,Long Sun,Hua Wu,Haojun Chen
出处
期刊:Clinical Nuclear Medicine
[Ovid Technologies (Wolters Kluwer)]
日期:2022-04-29
卷期号:47 (10): 906-907
被引量:24
标识
DOI:10.1097/rlu.0000000000004260
摘要
Abstract Many recent studies began to explore the therapeutic potential of FAP-targeted radionuclide therapy for refractory cancers. In this case, we presented the experience of multiple cycles of 177 Lu-FAPI-46 radionuclide therapy in a 34-year-old man with radioiodine-refractory differentiated thyroid cancer (RAIR-DTC). Intense radiotracer uptake was observed in RAIR-DTC metastatic lesions on the pretreatment 68 Ga-FAPI PET/CT and posttherapeutic scintigraphy. Follow-up examinations after 4 cycles of 177 Lu-FAPI-46 treatment revealed stable metastatic lesions, resulting in stable disease. This case demonstrated the potential feasibility of 177 Lu-FAPI-46 in the treatment of advanced RAIR-DTC; further research on improving the FAP-targeting vector may be necessary.
科研通智能强力驱动
Strongly Powered by AbleSci AI